Bank of America Corp DE Acquires 421,645 Shares of Adaptive Biotechnologies Corporation $ADPT
Bank of America Corp DE has increased its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 52.3% in the first quarter, acquiring an additional 421,645 shares and bringing its total holdings to 1,227,917 shares valued at $17,043,000. This comes amidst mixed sentiment for ADPT, with analysts maintaining a "Moderate Buy" consensus and significant institutional ownership, yet the company reported a quarterly EPS miss and experienced notable insider selling.
Adaptive Biotechnologies (NASDAQ:ADPT) Director Robert Hershberg Sells 30,664 Shares of Stock
Robert Hershberg, a director at Adaptive Biotechnologies (NASDAQ:ADPT), sold 30,664 shares of the company's stock for approximately $748,202, reducing his direct holdings by nearly 40%. The sale occurred as ADPT shares traded near their 12-month high, despite the company missing EPS estimates in its recent quarterly report. Analysts maintain a "Moderate Buy" rating with a consensus price target of $24.42, and several firms have recently raised their price targets.
Adaptive Biotech (NASDAQ: ADPT) ex-officer to sell 402,160 shares
Adaptive Biotechnologies Corp (ADPT) former officer Harlan Robins plans to sell 402,160 shares of common stock, valued at over $10.2 million, through Goldman Sachs & Co. LLC. These shares were acquired as compensation via stock options in 2022 and are slated for a cashless exercise/same-day sale. The filing also details multiple previous open-market sales by Robins within the last three months.
Adaptive Biotechnologies (NASDAQ: ADPT) director exercises option at $6.32 strike
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg exercised a stock option for 15,000 shares at $6.32 per share on August 18, 2026. He then sold a total of 30,664 shares in two transactions at weighted average prices of $24.39 and $24.41. The option was fully vested and would have expired on October 18, 2026.
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares
Adaptive Biotechnologies Corp (NASDAQ:ADPT) CEO Chad M. Robins sold approximately $14.88 million worth of company stock on August 17 and 18, 2026, following the exercise of stock options. The sales occurred as the stock neared its 52-week high after a significant 107% gain over the past year. Despite an adjusted loss per share in Q2, the company reported strong revenue growth, leading BTIG and Guggenheim to raise their price targets for ADPT.
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares By Investing.com
Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold approximately $14.88 million worth of company stock on August 17 and 18, 2026, following the exercise of stock options. The sales occurred as the stock neared its 52-week high after a 107% gain over the past year. Despite a recent earnings miss, analysts from BTIG and Guggenheim have raised their price targets for Adaptive Biotechnologies, citing strong revenue growth and impressive performance in its core minimal residual disease business.
Adaptive Biotechnologies director Neupert sells $3.1m in stock
Peter M. Neupert, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 124,690 shares of common stock for over $3.1 million on August 17, 2026, after exercising options for 15,000 shares. The stock is near its 52-week high, having returned 107% in the past year, though some platforms suggest it is overvalued. This follows recent positive news for the company, including exceeding revenue expectations and price target increases from BTIG and Guggenheim due to strong growth in its minimal residual disease business.
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 278,676 Shares
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins sold 278,676 shares of the company's stock for over $6.82 million on August 18th, reducing his direct stake by 11.33%. Despite a quarterly loss of $0.25 per share, which missed analyst expectations, the company's revenue increased by 21.5% year-over-year. Analysts maintain a "Moderate Buy" rating with an average price target of $24.42, and institutional investors own a significant 99.17% of the stock.
Adaptive Biotechnologies (ADPT) director sells stock after option exercise
Peter M. Neupert, a director at Adaptive Biotechnologies Corp (ADPT), reported exercising 15,000 stock options at $6.32 per share and subsequently selling 124,690 shares of common stock. The sales were conducted in open-market transactions at weighted average prices between $25.10 and $25.27 per share, generating approximately $3.14 million in gross proceeds. This transaction fully exhausted the exercised option grant and significantly reduced his direct common stock holdings.
Adaptive Biotechnologies (ADPT) CEO sells 600K shares after exercising options
Adaptive Biotechnologies Corp (ADPT) CEO and Chairman Chad M. Robins exercised stock options for 600,000 shares and subsequently sold all 600,000 shares in open-market transactions on August 17 and 18, 2026. The options were exercised at $6.55 per share, and the shares were sold at weighted average prices between approximately $24 and $26 per share. This exercise-and-sell pattern resulted in an approximate pre-tax spread of $10.95 million for Robins.
Adaptive Biotechnologies (NASDAQ: ADPT) ex-officer plans new share sale
Harlan Robins, a former officer of Adaptive Biotechnologies (NASDAQ: ADPT), plans to sell up to 215,632 shares of common stock through Goldman Sachs & Co. LLC under Rule 144, valued at approximately $5.5 million. The shares were acquired as compensation via stock options in March 2022 and the disposition is described as a cashless exercise and same-day sale. The filing also details multiple prior stock sales by Robins over the last three months.
Adaptive Biotechnologies stock hits 52-week high at 26.16 USD
Adaptive Biotechnologies (ADPT) stock reached a new 52-week high of $26.16, marking a nearly 100% change over the past year. Despite this strong performance and investor confidence, InvestingPro analysis suggests the stock might be overvalued with high volatility. The company recently reported a Q2 earnings miss but exceeded revenue expectations, leading BTIG and Guggenheim to raise price targets and maintain Buy ratings.
66,000 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Handelsbanken Fonder AB
Handelsbanken Fonder AB recently acquired 66,000 shares of Adaptive Biotechnologies Corporation ($ADPT) valued at approximately $1.42 million. This purchase is part of broader institutional investor activity, with hedge funds and institutions owning 99.17% of the company. Despite positive analyst ratings and strong revenue growth, the company missed earnings per share estimates, and insiders have sold a significant number of shares recently.
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans more sales after $7.96M already sold
Adaptive Biotechnologies insider Chad Robins has filed a Rule 144 notice to sell 278,676 shares of common stock, valued at $6.84 million, through Goldman Sachs & Co. LLC. This follows prior sales of 321,324 shares worth $7.96 million over the last three months. The shares for the new sale were originally granted as stock options on February 7, 2018, and will be disposed of via a cashless exercise/same-day sale.
Adaptive Biotechnologies (ADPT) ex-officer plans cashless option share sale
A former officer of Adaptive Biotechnologies (ADPT), Harlan Robins, intends to sell 261,044 shares of common stock under Rule 144, valued at approximately $6.4 million. These shares were acquired as stock option compensation and will be sold via a cashless exercise and same-day sale through Goldman Sachs & Co. LLC. The filing also reveals multiple prior stock sales by Robins within the last three months, totaling over 1.2 million shares.
Adaptive Biotechnologies (NASDAQ: ADPT) director plans to resell 30,664 shares
Adaptive Biotechnologies (ADPT) director Robert M. Hershberg has filed a Form 144 notice to potentially resell up to 30,664 shares of common stock. The proposed sale has an aggregate market value of $748,303.36 and includes shares from a stock option exercise and restricted stock. This filing is a notice of intent and does not confirm the actual execution of the transactions.
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins, co-founder of Adaptive Biotechnologies, has launched a new Bellevue startup called Harell Data with $15 million in funding. The company aims to provide a secure platform for data creators to commercialize their proprietary research datasets by connecting them with AI modelers, addressing the current lack of fair compensation for high-quality scientific data used in AI development. Harell Data will allow machine learning groups to train models without accessing the raw data directly, offering revenue sharing to data owners and enabling solutions to complex scientific problems across various disciplines.
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans multimillion stock sale
Harlan Robins, an insider at Adaptive Biotechnologies (ADPT), has filed a Form 144 indicating an intent to sell 300,992 shares of common stock, valued at over $7.45 million, through Goldman Sachs & Co. LLC on or after August 17, 2026. The shares were acquired through performance awards and stock options, including a cashless exercise component. This filing also details several prior common stock sales by Robins in June and July 2026.
Adaptive Biotechnologies (NASDAQ: ADPT) lines up six-figure share sale for 2026
Adaptive Biotechnologies Corp. (ADPT) has filed a Form 144, indicating a planned sale of 124,690 common shares valued at approximately $3.14 million. The sale, scheduled for August 17, 2026, will be handled by Morgan Stanley Smith Barney LLC and includes shares from stock option exercises, restricted stock grants, and previously exercised shares. This filing provides transparency regarding future stock transactions by insiders.
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Dimensional Fund Advisors LP significantly reduced its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 86.4% in the first quarter, selling over 1.19 million shares and retaining 188,338 shares. Despite this, institutional investors still hold 99.17% of the stock. Adaptive Biotechnologies reported a 21.5% increase in quarterly revenue year-over-year but missed EPS estimates, while analysts generally maintain a "Moderate Buy" rating with an average price target of $24.42, even as insiders have sold a substantial amount of shares.
576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP
Wasatch Advisors LP has acquired 576,266 shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) worth approximately $12.4 million, bringing institutional ownership in the company to 99.17%. Despite a reported wider-than-expected quarterly loss, Adaptive Biotechnologies saw a 21.5% year-over-year revenue increase. The stock is trading near its 52-week high, with analysts maintaining a "Moderate Buy" rating, although company insiders have recently sold a significant number of shares.
Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan
Adaptive Biotechnologies' Chief Commercial Officer, MRD, Susan Bobulsky, sold 3,000 shares of common stock at $25.00 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on December 16, 2025. Following the sale, Bobulsky directly holds 396,989 shares of ADPT.
Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales
Adaptive Biotechnologies (ADPT) stock appears fairly valued based on its discounted cash flow model, which places its intrinsic value close to its current share price. However, the stock looks expensive when evaluated using market multiples, particularly its P/S ratio, which is significantly higher than industry averages. The analysis suggests that while future revenue growth could justify the current valuation, the timing and scale of cash flows present a key risk.
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock
Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of the company, which holds a "Moderate Buy" consensus rating from analysts.
Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com
Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high after a significant gain. Despite positive analyst ratings and revenue growth, InvestingPro analysis suggests the company may be overvalued.
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge
Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment with 7 buy ratings. Its robust free cash flow and bullish technical indicators suggest potential for long-term growth in the healthcare sector.
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com
Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This surge follows positive Q2 results where revenue surpassed estimates, and analysts from BTIG and Guggenheim raised price targets due to robust growth in its minimal residual disease business.
ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares
A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The filing also details prior Rule 10b5-1 plan sales by Susan Bobulsky over the last three months, including multiple transactions in June and July 2026.
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD
Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $25.04, reflecting a 104% increase over the past year and a market capitalization of approximately $3.95 billion. This growth is supported by a 50% revenue increase in the last twelve months, signaling strong investor confidence. Despite trading above its Fair Value, the company's robust performance is further evidenced by recent analyst upgrades and strong revenue growth in its core minimal residual disease business.
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com
Adaptive Biotechnologies (ADPT) stock reached a new 52-week high of $25.04, reflecting a 104% increase over the past year and a market capitalization of $3.95 billion. This surge is supported by 50% revenue growth and strong performance in its minimal residual disease business. Despite a recent earnings miss, analyst ratings remain positive with increased price targets, indicating continued investor confidence in the company's growth trajectory.
Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT
Renaissance Technologies LLC has acquired 239,800 shares of Adaptive Biotechnologies Corporation, valued at approximately $3.33 million, marking a new stake in the company. Institutional investors collectively hold 99.17% of Adaptive Biotechnologies. The company reported better-than-expected quarterly revenue but missed earnings estimates, while analysts maintain a "Moderate Buy" rating with an average price target of $24.42.
ADAPTIVE BIOTECHNOLOGIES CORP : PIPER SANDLER RAISES TARGET PRICE TO $27.50 FROM $20.00
Piper Sandler has increased its target price for Adaptive Biotechnologies Corp to $27.50 from $20.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The information was reported by Reuters.
Adaptive Biotechnologies (NASDAQ: ADPT) raises $345M in 2031 notes
Adaptive Biotechnologies (ADPT) has issued $345 million in 0% convertible senior notes due 2031, using part of the proceeds to repurchase revenue interests and common stock. The company reported a Q2 2026 revenue of $71.6 million, an increase from the previous year, driven by MRD services, but also a widened net loss of $39.8 million. ADPT plans to separate its MRD and Immune Medicine businesses by the end of 2026, focusing Immune Medicine on its TCR-antigen dataset and target discovery.
Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary
Adaptive Biotechnologies Corp (ADPT) reported Q2 2026 financial results, with revenue reaching $71.6 million, an increase from $58.9 million in the previous year. The company recorded a net loss of $(39.8) million and a diluted loss per share of $(0.25). Key drivers included a significant rise in minimal residual disease (MRD) revenue, while Immune Medicine revenue declined due to the termination of a collaboration, leading to a planned repositioning of that business segment.
Adaptive Biotechnologies CCO Susan Bobulsky sells $31,176 shares
Susan Bobulsky, CCO of Adaptive Biotechnologies (NASDAQ:ADPT), sold
Form 4 Adaptive Biotechnologies Corp For: 3 August By Investing.com
This article from Investing.com announces the filing of Form 4 for Adaptive Biotechnologies Corp on August 3rd. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol ADPT and its intraday price performance, indicating a 2.39% increase.
Adaptive Biotechnologies (NASDAQ: ADPT) CCO trades 1,299 shares under plan
Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 1,299 shares of common stock on July 30, 2026, at $24.00 per share, totaling $31,176. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, Bobulsky directly holds 399,989 shares in the company.
Adaptive Biotechnologies Corp (ADPT) Shares Fall 6.7% -- GF Value Says Still Overvalued
Adaptive Biotechnologies Corp (ADPT) shares dropped 6.7%, and GuruFocus's GF Value suggests the stock is 125.0% overvalued at $22.57 compared to its estimated fair value of $10.03. Despite an above-average GF Score of 66/100, driven by strong growth and momentum ranks, its financial strength and profitability are concerning, and insider selling further signals caution for investors.
Adaptive Biotechnologies Corp (ADPT) Institutional Confidence
The article discusses the institutional confidence score for Adaptive Biotechnologies Corp (ADPT), which is currently 10.00, ranking it 1st in the Biotechnology & Medical Research industry. Institutional shareholding stands at 94.68%, with a slight quarter-over-quarter decrease. Andreas Halvorsen is highlighted as the largest institutional shareholder, and other major institutional investors and their recent changes in holdings are listed.
Adaptive Biotechnologies (NASDAQ: ADPT) insider reports Rule 10b5-1 stock sales
Adaptive Biotechnologies insider Susan Bobulsky has filed planned stock sales under a Rule 10b5-1 trading plan. The Form 144 filing details multiple open-market sales of common shares on NASDAQ in June and July 2026, totaling 26,487 shares for proceeds of $521,214.00. The sales are linked to Restricted Stock Units granted on March 4, 2023.
Adaptive Biotechnologies Number of Employees 2026 | Employee Count & Headcount Data
Adaptive Biotechnologies (NASDAQ: ADPT) had approximately 632 employees worldwide as of March 2026, a decline of 18.7% from 777 employees in 2023. Despite the overall headcount decline, the company is actively hiring, with 53 active job postings in 2026, a 40.9% increase from 2025. The workforce is primarily concentrated in the United States, and the average salary is $152,501.
Adaptive Biotechnologies stock hits 52-week high at 23.25 USD
Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $23.25, reflecting a significant 120.31% increase over the past year. Despite its robust revenue growth of 56% over the last twelve months, InvestingPro analytical data suggests the stock might be overvalued. Recent Q2 results showed mixed performance with an adjusted loss per share but revenue exceeding expectations, and analysts have raised price targets citing strong clonoSEQ test growth.
Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Adaptive Biotechnologies Corp (AD
ETFs Investing in Adaptive Biotechnologies Corp. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (A2PLR5). It provides detailed financial data for each ETF, including market value, weight of Adaptive Biotechnologies stock, issuer, management style, focus, expense ratio, AUM, price change, and 3-year NAV total return. The ETFs cover a range of investment strategies, from small-cap and growth to healthcare and genomic-related themes.
Adaptive Biotechnologies (ADPT) Releases Q2 2026 Earnings: Revenue Growth but Still Unprofitable
Adaptive Biotechnologies (ADPT) reported Q2 2026 revenues of $71.6 million, marking a 21.5% year-over-year increase and surpassing analyst estimates. Despite this revenue growth and improved gross profit, the company remained unprofitable, posting a net loss of $39.8 million. Insider trading data shows significant sales by executives, while institutional investors show mixed activity in their holdings.
Adaptive Biotechnologies: Q2 Earnings Snapshot
This article provides a brief Q2 earnings snapshot for Adaptive Biotechnologies. No specific financial details or further information are available in the provided text.
Adaptive Biotechnologies (Nasdaq: ADPT) boosts MRD 2026 guidance after Q2 revenue hits $71.6M
Adaptive Biotechnologies (ADPT) announced strong second-quarter 2026 results, with total revenue reaching $71.6 million, a 22% year-over-year increase, primarily driven by its Minimal Residual Disease (MRD) segment which grew 33%. The company raised its full-year 2026 MRD revenue guidance to $268–$278 million and completed a $345 million convertible senior notes offering, enhancing its financial flexibility. Co-founder and Chief Scientific Officer Harlan Robins will transition to a strategic consultant role, focusing on MRD R&D and the planned separation of the Immune Medicine business.
Adaptive Biotechnologies' MRD Business Grew 33%; clonoSEQ Volume Reached 36,111
Adaptive Biotechnologies (ADPT) reported strong Q2 2026 financial results, with overall revenue up 22% to $71.6 million, largely driven by its Minimal Residual Disease (MRD) business, which grew 33% year-over-year. The company also announced plans to separate its MRD and Immune Medicine businesses, completed a $345 million convertible senior notes offering, and raised its full-year 2026 MRD revenue guidance to $268–$278 million. Despite an overall net loss of $39.9 million, Adjusted EBITDA loss narrowed significantly to $0.7 million.
Adaptive Biotechnologies: Q2 Earnings Snapshot
This article provides an earnings snapshot for Adaptive Biotechnologies (NASDAQ: ADPT) for its second quarter. The content appears to be a placeholder or an incomplete article, as it lacks any financial data, results, or detailed information beyond the title.
Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis
Adaptive Biotechnologies Corp (ADPT) has a current financial score of 7.62, ranking 97 out of 386 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $70.87 million, marking a 35.14% year-over-year increase, while net profit also saw a 32.89% year-over-year increase. Despite these gains, several key financial metrics like cash and cash equivalents, total assets, and free cash flow have not yet been disclosed by the company.
